Please use this identifier to cite or link to this item:
Title: FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx
Authors: DUTRA, Roberta LelisCARVALHO, Marcos Brasilino deSANTOS, Marcelo dosMERCANTE, Ana Maria da CunhaGAZITO, DianaCICCO, Rafael deTAJARA, Eloiza HelenaLOURO, Iuri DrumondSILVA, Adriana Madeira Alvares da
Citation: PLOS ONE, v.7, n.11, article ID e50747, 9p, 2012
Abstract: Background: Fibroblast growth factor receptor 4 (FGFR4) is a member of a receptor tyrosine kinase family of enzymes involved in cell cycle control and proliferation. A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas. The present study evaluated the prognostic significance of FGFR4 in oral and oropharynx carcinomas, finding an association of FGFR4 expression and Gly388Arg genotype with tumor onset and prognosis. Patients and Methods: DNA from peripheral blood of 122 patients with oral and oropharyngeal squamous cell carcinomas was used to determine FGFR4 genotype by PCR-RFLP. Protein expression was assessed by immunohistochemistry (IHC) on paraffin-embedded tissue microarrays. Results: Presence of allele Arg388 was associated with lymphatic embolization and with disease related premature death. In addition, FGFR4 low expression was related with lymph node positivity and premature relapse of disease, as well as disease related death. Conclusion: Our results propose FGFR4 profile, measured by the Gly388Arg genotype and expression, as a novel marker of prognosis in squamous cell carcinoma of the mouth and oropharynx.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Files in This Item:
File Description SizeFormat 
art_DUTRA_FGFR4_Profile_as_a_Prognostic_Marker_in_Squamous_2012.PDFpublishedVersion (English)455.88 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.